KR20120089459A - 키나제 저해제로서 5,6-바이사이클릭 헤테로아릴-함유 우레아 화합물 - Google Patents

키나제 저해제로서 5,6-바이사이클릭 헤테로아릴-함유 우레아 화합물 Download PDF

Info

Publication number
KR20120089459A
KR20120089459A KR1020127006772A KR20127006772A KR20120089459A KR 20120089459 A KR20120089459 A KR 20120089459A KR 1020127006772 A KR1020127006772 A KR 1020127006772A KR 20127006772 A KR20127006772 A KR 20127006772A KR 20120089459 A KR20120089459 A KR 20120089459A
Authority
KR
South Korea
Prior art keywords
pyrrolo
urea
ylmethyl
pyridin
indol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020127006772A
Other languages
English (en)
Korean (ko)
Inventor
샨 지앙
싱롱 싱
치산 왕
렌 콩
Original Assignee
에즈셉피온 파마슈티컬즈, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에즈셉피온 파마슈티컬즈, 인코포레이티드 filed Critical 에즈셉피온 파마슈티컬즈, 인코포레이티드
Publication of KR20120089459A publication Critical patent/KR20120089459A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020127006772A 2009-08-24 2010-08-20 키나제 저해제로서 5,6-바이사이클릭 헤테로아릴-함유 우레아 화합물 Withdrawn KR20120089459A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23627409P 2009-08-24 2009-08-24
US61/236,274 2009-08-24
PCT/CN2010/076199 WO2011023081A1 (en) 2009-08-24 2010-08-20 5,6-bicyclic heteroaryl-containing urea compounds as kinase inhibitors

Publications (1)

Publication Number Publication Date
KR20120089459A true KR20120089459A (ko) 2012-08-10

Family

ID=43627250

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127006772A Withdrawn KR20120089459A (ko) 2009-08-24 2010-08-20 키나제 저해제로서 5,6-바이사이클릭 헤테로아릴-함유 우레아 화합물

Country Status (20)

Country Link
US (1) US8648086B2 (https=)
EP (1) EP2470533A4 (https=)
JP (1) JP2013502444A (https=)
KR (1) KR20120089459A (https=)
CN (1) CN102066372B (https=)
AU (1) AU2010289143A1 (https=)
BR (1) BR112012003462A2 (https=)
CA (1) CA2769151A1 (https=)
CO (1) CO6491087A2 (https=)
EA (1) EA201290073A1 (https=)
EC (1) ECSP12011691A (https=)
IL (1) IL218114A0 (https=)
IN (1) IN2012DN01983A (https=)
MA (1) MA33559B1 (https=)
MX (1) MX2012002317A (https=)
PH (1) PH12012500366A1 (https=)
SG (1) SG178092A1 (https=)
TN (1) TN2012000042A1 (https=)
WO (1) WO2011023081A1 (https=)
ZA (1) ZA201200890B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2599458T3 (es) 2008-10-14 2017-02-01 Sunshine Lake Pharma Co., Ltd. Compuestos y métodos de uso
EP2408300B1 (en) 2009-03-21 2016-05-11 Sunshine Lake Pharma Co., Ltd. Amino ester derivatives, salts thereof and methods of use
US20130165475A1 (en) * 2010-09-01 2013-06-27 Ascepion Pharmaceuticals, Inc. Deuterium-enriched heterocyclic compounds as kinase inhibitors
WO2012075381A1 (en) 2010-12-03 2012-06-07 Epizyme, Inc. Substituted purine and 7 - deazapurine compounds as modulators of epigenetic enzymes
CN102408426B (zh) * 2011-09-14 2013-07-10 湖南有色凯铂生物药业有限公司 取代的芳香脲类化合物及其作为抗癌药物的应用
FR2985257B1 (fr) * 2011-12-28 2014-02-14 Sanofi Sa Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique
CN103420895A (zh) * 2012-05-18 2013-12-04 苏州爱斯鹏药物研发有限责任公司 一种4-氨基吲哚的制备方法
WO2014026198A1 (en) 2012-08-10 2014-02-13 Epizyme, Inc. Inhibitors of protein methyltransferase dot1l and methods of use thereof
US9597348B2 (en) 2012-09-06 2017-03-21 Epizyme, Inc. Method of treating leukemia
JP2016517426A (ja) 2013-03-15 2016-06-16 エピザイム，インコーポレイティド 置換プリン化合物の合成方法
CN103613580B (zh) * 2013-09-03 2016-02-10 遵义医学院 用于抗肿瘤药物的3-羟基吲哚-2-酮类化合物或其药学上能够接受的盐
CN106279154A (zh) * 2016-08-02 2017-01-04 叶芳 一种7‑氮杂吲哚‑3‑甲醛的制备方法
CN108191874B (zh) * 2018-01-16 2019-11-29 成都施贝康生物医药科技有限公司 一种C-Kit抑制剂及其应用
WO2019228252A1 (zh) * 2018-06-01 2019-12-05 杭州阿诺生物医药科技有限公司 一种高活性csf1r抑制剂化合物
EP3833762A4 (en) 2018-08-09 2022-09-28 Verseau Therapeutics, Inc. Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof
WO2022123319A1 (en) * 2020-12-11 2022-06-16 Ildong Pharmaceutical Co., Ltd. Biased agonists of opioid receptors
US20240300939A1 (en) 2021-06-14 2024-09-12 Scorpion Therapeutics, Inc. Urea derivatives which can be used to treat cancer

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3928177A1 (de) 1989-04-08 1991-02-28 Thomae Gmbh Dr K Benzimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
GB9412719D0 (en) 1994-06-24 1994-08-17 Erba Carlo Spa Substituted azaindolylidene compounds and process for their preparation
GB9604361D0 (en) 1996-02-29 1996-05-01 Pharmacia Spa 4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors
US6300325B1 (en) 1997-01-23 2001-10-09 Smithkline Beecham Corporation IL-8 receptor antagonists
EP1161423B1 (de) * 1999-03-08 2004-11-10 Bayer HealthCare AG Thiazolylharnstoff-derivate und ihre verwendung als antivirale mittel
CO5190696A1 (es) 1999-06-16 2002-08-29 Smithkline Beecham Corp Antagonistas de los receptores il-8
US6525067B1 (en) * 1999-11-23 2003-02-25 Pfizer Inc Substituted heterocyclic derivatives
US20030158188A1 (en) 2002-02-20 2003-08-21 Chih-Hung Lee Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
US7074805B2 (en) 2002-02-20 2006-07-11 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
CN100497302C (zh) * 2002-09-05 2009-06-10 神经研究公司 二芳基脲衍生物和它们作为氯通道阻滞剂的用途
GB0226724D0 (en) 2002-11-15 2002-12-24 Merck Sharp & Dohme Therapeutic agents
UA80171C2 (en) 2002-12-19 2007-08-27 Pfizer Prod Inc Pyrrolopyrimidine derivatives
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
US7015233B2 (en) 2003-06-12 2006-03-21 Abbott Laboratories Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor
GB0322016D0 (en) 2003-09-19 2003-10-22 Merck Sharp & Dohme New compounds
CA2546192C (en) * 2003-11-17 2010-04-06 Pfizer Products Inc. Pyrrolopyrimidine compounds useful in treatment of cancer
CN1925855B (zh) 2003-12-19 2010-06-16 普莱希科公司 开发Ret调节剂的化合物和方法
JP2007518823A (ja) * 2004-01-23 2007-07-12 アムゲン インコーポレイテッド キノリン、キナゾリン、ピリジン、及びピリミジン化合物と炎症、血管新生、及び癌に対する治療におけるそれら化合物の用途
AR049333A1 (es) 2004-04-02 2006-07-19 Vertex Pharma Azaindoles inhibidores de proteinquinasas rock y otras proteinas quinasas. composiciones farmaceuticas.
JP2008503473A (ja) 2004-06-17 2008-02-07 プレキシコン，インコーポレーテッド Ｃ−ｋｉｔ活性を調節する化合物
US7173031B2 (en) 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
CA2573573A1 (en) 2004-07-27 2006-02-09 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
US7626021B2 (en) 2004-07-27 2009-12-01 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
NZ555318A (en) 2004-11-24 2011-01-28 Abbott Lab Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof
AR054416A1 (es) 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
EP1858879B1 (en) 2005-01-14 2012-06-06 Gilead Connecticut, Inc. 1,3-diaryl substituted ureas as modulators of kinase activity
US20090111805A1 (en) 2005-02-24 2009-04-30 Pfizer Inc. Bicyclic heteroaromatic derivatives useful as anticancer agents
WO2007024294A2 (en) 2005-05-03 2007-03-01 Cgi Pharmaceuticals, Inc. Certain substituted ureas, as modulators of kinase activity
US7846941B2 (en) 2005-05-17 2010-12-07 Plexxikon, Inc. Compounds modulating c-kit and c-fms activity and uses therefor
UA95244C2 (ru) 2005-06-22 2011-07-25 Плексикон, Инк. Соединения и способ модулирования активности киназ, и показания для их применения
FR2889526B1 (fr) 2005-08-04 2012-02-17 Aventis Pharma Sa 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
JP5072595B2 (ja) * 2005-08-05 2012-11-14 中外製薬株式会社 マルチキナーゼ阻害剤
JP2007099642A (ja) * 2005-09-30 2007-04-19 Tsumura & Co 含窒素複素環化合物、その製造方法およびそれを用いた医薬組成物
PT1940844E (pt) * 2005-10-28 2010-01-06 Scripps Research Inst Compostos e composições como inibidores de proteína-quinase
CN101365684A (zh) 2005-10-28 2009-02-11 艾博特公司 抑制trpv1受体的吲唑衍生物
EA200870117A1 (ru) 2005-12-23 2008-12-30 Смитклайн Бичам Корпорейшн Азаиндоловые ингибиторы аурора-киназ
EP1981887A2 (en) 2006-02-01 2008-10-22 SmithKline Beecham Corporation Pyrrolo[2,3,b]pyridine derivatives useful as raf kinase inhibitors
CN101058561B (zh) 2006-04-19 2011-01-26 苏州爱斯鹏药物研发有限责任公司 用于抑制蛋白激酶的二苯脲衍生物及其组合物和用途
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
WO2008079909A1 (en) 2006-12-21 2008-07-03 Plexxikon, Inc. Pyrrolo [2,3-b] pyridines as kinase modulators
PE20121126A1 (es) 2006-12-21 2012-08-24 Plexxikon Inc Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa
WO2008125014A1 (fr) * 2007-04-13 2008-10-23 Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. Composés d'urée, leurs procédés de préparation et leurs utilisations pharmaceutiques

Also Published As

Publication number Publication date
BR112012003462A2 (pt) 2016-02-23
ECSP12011691A (es) 2012-04-30
US8648086B2 (en) 2014-02-11
MA33559B1 (fr) 2012-09-01
EP2470533A4 (en) 2013-01-23
IN2012DN01983A (https=) 2015-07-24
US20120122895A1 (en) 2012-05-17
MX2012002317A (es) 2012-06-25
JP2013502444A (ja) 2013-01-24
CA2769151A1 (en) 2011-03-03
CN102066372A (zh) 2011-05-18
EA201290073A1 (ru) 2013-01-30
TN2012000042A1 (en) 2013-09-19
CN102066372B (zh) 2014-09-17
ZA201200890B (en) 2012-10-31
CO6491087A2 (es) 2012-07-31
AU2010289143A1 (en) 2012-02-16
WO2011023081A1 (en) 2011-03-03
EP2470533A1 (en) 2012-07-04
PH12012500366A1 (en) 2012-10-22
SG178092A1 (en) 2012-03-29
IL218114A0 (en) 2012-04-30

Similar Documents

Publication Publication Date Title
KR20120089459A (ko) 키나제 저해제로서 5,6-바이사이클릭 헤테로아릴-함유 우레아 화합물
JP6790040B2 (ja) Ｆａｓｎを阻害するための新規化合物および組成物
JP5001179B2 (ja) 化学物質
CN105324378B (zh) 可用作fgfr激酶调节剂的喹唑啉酮衍生物
CN104507944B (zh) 作为fgfr抑制剂的蝶啶
TWI494311B (zh) 作為新的ＳｙＫ抑制劑的取代的吡啶并吡嗪化合物
JP2019163287A (ja) 三環式誘導体化合物、その製造方法及びそれを含む薬学的組成物
CN102596200A (zh) 作为TGF-β受体激酶抑制剂的杂芳基氨基喹啉类
TW200524928A (en) Substituted naphthyridine derivatives as inhibitors of macrophage migration inhibitory factor and their use in the treatment of human diseases
KR20140096033A (ko) 신규 화합물
JP2013536868A (ja) 癌などの疾患の治療のためのｎａｍｐｔ阻害剤としての４−｛［（ピリジン−３−イル−メチル）アミノカルボニル］アミノ｝ベンゼン−スルホン誘導体
TWI601724B (zh) 咪唑並喹啉類衍生物及其可藥用鹽、其製備方法及其在醫藥上的應用
WO2016042341A1 (en) Pyrrolcarboxamide derivatives for the inhbition of erk5
CN103313970A (zh) 新型二环式化合物或其盐
JP2013536806A (ja) キナーゼ阻害剤としての重水素化複素環式化合物
KR20240009929A (ko) Parp 억제제로서 치환된 융합 이환 화합물 및 이의 용도
CN110407839B (zh) 含杂芳基酰胺结构的三唑并杂环类化合物的制备及应用
CN108117551B (zh) 取代(1H-吡唑[3,4-b]吡啶)脲类化合物及其抗肿瘤用途
RU2827699C1 (ru) Бициклические гетероциклические ингибиторы fgfr4, фармацевтические композиции и составы, содержащие их, и их применение
WO2024105364A1 (en) Heterocyclic inhibitors of cdc-like kinases
TW201311681A (zh) 氘代雜環化合物激酶抑制劑
WO2025113625A1 (zh) 作为pkmyt1抑制剂的杂芳环和杂双环化合物及其应用
EP4036086A1 (en) Heterocyclic derivative and use thereof
HK1157779A (en) 5,6-bicyclic heteroaryl-containing urea compounds as kinase inhibitors
HK1173370A (en) Heteroarylaminoquinolines as tgf-beta receptor kinase inhibitors

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20120315

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid